Tisotumab Vedotin以前治疗的复发或转移性宫颈癌。

文章的细节

引用

复制到剪贴板

香港DS, Concin N, Vergote我de Bono JS Slomovitz BM, Y, Arkenau HT, Machiels JP, Spicer摩根富林明,琼斯R,福斯特博士Cornez N, Gennigens C,约翰逊ML, Thistlethwaite FC, Rangwala RA, Ghatta年代,Windfeld K,哈里斯JR,拉森联合国,科尔曼RL

Tisotumab Vedotin以前治疗的复发或转移性宫颈癌。

癌症研究杂志2020年3月15日,26 (6):1220 - 1228。doi: 10.1158 / 1078 - 0432. - ccr - 19 - 2962。Epub 2019年12月3。

PubMed ID

31796521 (在PubMed

]

文摘

目的:组织因子(TF)在宫颈癌是一个潜在的目标,因为它是经常高度表达和与不良预后相关。Tisotumab vedotin, first-in-class临床实验的抗体药物共轭针对TF,展示了令人鼓舞的活动实体肿瘤。在这里,我们报告数据从201年innovaTV宫颈癌组I / II期研究(NCT02001623)。患者和方法:患者复发或转移性宫颈癌收到tisotumab vedotin 2.0毫克/公斤每3周直到进行性疾病,不可接受的毒性,或同意撤军。的主要目标是安全性和耐受性。二级目标包括抗肿瘤活性。结果:55岁的患者中,51%的人接受之前> / = 2行治疗复发或转移性设置;之前有67%贝伐单抗+双重化疗。百分之五十一的患者有鳞状细胞癌。最常见的3/4级治疗诱发不良事件(AEs)贫血(11%)、疲劳(9%)、呕吐(7%)。 No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective response rate (ORR) was 24% [95% confidence interval (CI): 13%-37%]. Median duration of response (DOR) was 4.2 months (range: 1.0(+)-9.7); four patients responded for >8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 17%-43%). Independent review outcomes were comparable, with confirmed ORR of 22% (95% CI: 12%-35%), median DOR of 6.0 months (range: 1.0(+)-9.7), and 6-month PFS rate of 40% (95% CI: 24%-55%). Tissue factor expression was confirmed in most patients; no significant association with response was observed. CONCLUSIONS: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Tisotumab vedotin

药物靶点

药物	目标	类	生物	药理作用	行动
Tisotumab vedotin	组织因子	蛋白质	人类	是的	抗体	细节